The Asia-Pacific digital pathology market size was valued at $143.32 Million in 2021, and is projected to reach $393.33 Million by 2031, registering a CAGR of 10.6% from 2022 to 2031.
Digital pathology is a computer-enabled, image-based information platform that helps for the management of information generated from digital slides. Digital pathology technology can aid a research pipeline in two ways. The first one is that the specified file storage and viewing applications may be used to arrange macroscopic images, tissue microarrays, and entire slide images. The second application of digital pathology in research is the development and implementation of image analysis techniques.
Digital pathology allows pathologists to review the sample digitally, on the computer screen, rather than peering through the microscope. This can help the pathologists by allowing them to review samples remotely (without having the need to be physically co-located with the sample) and can improve efficiency by relieving the stress and strain of using a microscope for long hours. Applications in healthcare include primary diagnosis, diagnostic consultation, intraoperative diagnosis, medical student and resident training, manual and semi-quantitative immunohistochemistry (IHC) review, clinical research, diagnostic decision assistance, peer review, and tumor boards. High throughput glass slide scanning, whole slide image quantitative analysis, instant web-based consultations with expert pathologists, and safe pathology data archiving are just a few examples of life science applications.
The market is expected to witness a moderate growth during the forecast period, owing to increasing adoption of digital pathology to enhance lab efficiency, increase in demand for accurate diagnostics because of increase in prevalence of cancer and development of new pathology system. For instance, in February 2019, Neuberg Diagnostics and OptraSCAN Inc., announced the launch of Global TELEPath Network for the pathologist community in UAE, India and South Africa under new joint venture namely Neuberg DIGIPATH.
Moreover, the increasing geriatric population that is susceptible to chronic conditions is also expected to boost the demand for technologically advanced diagnostic techniques.
However, high cost associated with digital pathology systems is expected to hinder the growth of market. On the other hand, introduction of affordable scanner for private pathology practices is anticipated to offer profitable growth opportunities for service providers in the future.
The Asia-Pacific digital pathology market is segmented on the basis of type, application, end user, and country. Based on type, the market is categorized into scanners, software, and storage & communication systems. Based on application, it is classified into teleconsultation, disease diagnosis, drug discovery, and training & education. Depending on end user, the market is fragmented into educational, clinical, and pharma & biotech companies. Country wise, it is analyzed across Japan, India, South-Korea, Australia, Malaysia, Indonesia, Myanmar, Taiwan, China, Vietnam, Singapore, New Zealand and Thailand.
What is the Impact of COVID-19 Pandemic on the APAC Digital Pathology Market?
Coronavirus (COVID-19) was discovered in late December, 2019 in the Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. Furthermore, the virus has high potential of lethality in the geriatric population. On March 11, 2020, the World Health Organization assessed that COVID-19 can be characterized as a pandemic.
The overall impact of COVID-19 remains positive on Asia-Pacific digital pathology market as increase in prevalence of COVID-19 has driven the demand for accurate diagnosis and treatment devices in several countries. Lockdown and restrictions related to social distancing led to an increase in the use of digital pathology solutions. Therefore, to reduce the workload of pathologists, Qritive launched its flagship product, Pantheon V2.0, in December 2020, which digitizes the entire pathology lab workflow and provides a platform for automated AI analysis with a single click. Also, it eliminates the need for multiple vendors at a pathology lab, thereby improving efficiency in terms of workflow.
The pandemic has also emphasized the importance of collaboration between key stakeholders in recovering, rebuilding, and strengthening the healthcare systems. These stakeholders include business organizations, hospitals, governments, as well as private sector partnerships. For instance, in 2021, Qritive collaborated with Singapore’s largest hospitals, including Singapore General Hospital (SGH) and National University Hospital (NUH), to create high-impact research that drives precision healthcare to make diagnosis fast, accurate, and affordable for pathologists and physicians. The sales of digital pathology scanners and storages decreased from 2019 to 2020 owing to a lack of interactions required for the demonstration of devices to clients and a lower number of pathological tests conducted in the laboratories. However, the demand for digital pathology solutions has increased after 2020. They help facilitate the continuity of patient care, reduce the risk of healthcare professionals being exposed to coronavirus, and prevent disruption of critical pathology services.
The COVID-19 pandemic has increased the need for diagnostics devices, which has driven the growth of the Asia-Pacific digital pathology market.
Asia-Pacific Digital Pathology Market Segmentation
The Asia-Pacific digital pathology market is segmented on the basis of type, application, end user, and country. Based on type, the market is categorized into scanners, software, and storage & communication systems. Based on application, it is classified into teleconsultation, disease diagnosis, drug discovery, and training & education. Depending on end user, the market is fragmented into educational, clinical, and pharma & biotech companies. Country wise, it is analyzed across Japan, India, South-Korea, Australia, Malaysia, Indonesia, Myanmar, Taiwan, China, Vietnam, Singapore, New Zealand and Thailand.
By Type
Scanners segment holds a dominant position in 2021 and would continue to maintain the lead over the forecast period. Owing to features provided by digital pathology Scanners, such as whole slide imaging systems that conduct automated assays as well as repeated data analysis across experiments and produce high quality images
Type Segment review
By type, the Asia-Pacific digital pathology market is categorized into scanners, software, and storage & communication systems. The scanners segment was the highest revenue contributor to the market in 2021. Owing to the advanced features provided by digital pathology scanners, such as whole slide imaging systems that conduct automated assays as well as repeated data analysis across experiments and produce high resolution images contributes to the growth of Asia-Pacific digital pathology market.
The software segment is anticipated to grow at a significant rate during the forecast period. Owing to the fact that digital pathology software provides a universal platform for pathology workflow to histo-technicians, pathologists, and administrators through diagnosis.
By Application
Disease Diagnostics segment is projected as one of the most lucrative segment. Owing to increase in use of digital pathology to diagnose various types of cancers and chronic diseases such as lung cancer, colorectal cancer, and breast cancer
Application Segment Review
By application, the Asia-Pacific digital pathology market is segmented into teleconsultation, disease diagnosis, drug discovery and training & education. The disease diagnosis segment was the highest revenue contributor to the market, owing to increase in use of digital pathology to diagnose various types of cancers and chronic diseases such as lung cancer, colorectal cancer, and breast cancer. .
The drug discovery segment is expected to grow at a considerable growth rate during the Asia-Pacific digital pathology market forecast period. Owing to increase in the productivity for drug development by reducing the volume of slides that need to be analyzed and provides increasingly accurate predictions of the images.
By End User
The Pharma & biotech companies segment was the highest revenue contributor to the market owing to the collaboration among various Pharma & biotech companies which further helps in the development of advanced diagnostics devices.
End user Segment Review
By end user, the pharma & biotech companies segment was the highest revenue contributor to the market owing to the collaboration among various pharma & biotech companies which further helps in the development of advanced diagnostics devices. .
The clinical segment is anticipated to be the fastest growing segment during the forecast period. Owing to increase in demand of clinical trial training applications which can be reformatted to drive quality improvement in routine practice , hence, contributing in the growth of Asia-Pacific digital pathology market.
By Country
India is expected to experience growth at the highest rate, registering a CAGR of 14.4% during the forecast period. Owing to rise in geriatric population and surge in use of digital pathology in drug development, data sharing with the payers, and high use of digital pathology for diagnosis of cancer.
Country Segment Review
Country wise, the Asia-Pacific digital pathology market is analyzed across Japan, India, South-Korea, Australia, Malaysia, Indonesia, Myanmar, Taiwan, China, Vietnam, Singapore, New Zealand and Thailand. The Japan market was dominant, in terms of revenue among other countries in 2021, owing to increase in key players for the digital diagnosis software development..
India is estimated to grow fastest during the forecast period. Rise in geriatric population and surge in use of digital pathology in drug development, data sharing with the payers, and high use of digital pathology for cancer cases are the factors that propel the growth of the market
The key players that operate in the Asia-Pacific digital pathology market includes Nikon Corporation, Hamamatsu photonics, Akoya Biosciences, Qritive, Aether AI, Danaher Corporation, Koninklijke Philips N.V, F-Hoffmann-La-Roche, Visopharma A/S and Indica Labs Inc.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the Asia-Pacific digital pathology market, and the current trends and future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the APAC digital pathology market.
Asia-Pacific Digital Pathology Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By End User |
|
 By Country |
|
 Key Market Players | Visiopharm A/S, Akoya Biosciences, Indica Labs Inc., Danaher Corporation, Roche, Qritive, Koninklijke Philips, Hamamatsu Photonics, Aether AI, Nikon Corporation |
Analyst Review
This section provides various opinions of the top-level CXOs in the Asia-Pacific digital pathology industry. Digital pathology is expected to witness significant growth in the near future, owing to increase in adoption of digital pathology over the traditional methods. In addition, the market is exhibiting high growth rate due to increase in usage of digital scanners. Moreover, surge in advantages offered by digital pathology and rise in prevalence of chronic & infectious diseases significantly contributes toward the growth of the market.
According to the perspectives of the CXOs of leading companies, technological advancements such as computational pathology (CPATH), multiple fiber-optic communications, robotic light microscopy, advancement in artificial intelligence (AI) and machine learning, ease of use, and cost-effective treatment boost growth in demand in developing regions further boost the market growth. However, high-cost of the digital pathology devices, lack of reimbursement policies and stringent regulatory policies regarding the utilization of digital pathology devices might hamper the market growth. Moreover, Asia-Pacific is expected to offer lucrative growth opportunities to the key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions.
The total market value of Asia-Pacific Digital Pathology market is $143.32 million in 2021.
The forecast period for Asia-Pacific Digital Pathology market is 2021 to 2031
The market value of Asia-Pacific Digital Pathology market in 2022 is $158.94 million.
The base year is 2021 in Asia-Pacific Digital Pathology market
Top companies such as Danaher Corporation, HAMAMTSU Photonics K.K, Indica Labs Inc., Koninklijke Philips N.V, Nikon Corporation, Roche, and Visiopharma A/S held a high market position in 2021.
Scanners segment dominated the global market in 2021, and expected to continue this trend throughout the forecast period due to the technological advancements and new product launch and thus is expected to drive the segment
Increase in demand for new technologies in Digital Pathology such as AI based digital systems, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
Japan is projected to account for a major share of the Asia-Pacific Digital Pathology market during the forecast period. The country accounted for 26% of the Asia-Pacific digital pathology market in 2021 and is expected to continue this trend during the forecast period.
Digital pathology is defined as an image-based information setting enabled by computer technology that allows the management and interpretation of pathology information generated from a digitized glass slide
Digital Pathology systems used for diagnosis of chronic & infectious diseases, and research & development of new cancer drugs.
The impact of the covid-19 pandemic on the market has largely been positive. The introduction of rapid test kits for the covid-19 virus has strongly aided sales. Investments in healthcare research are expected to continue rising for the foreseeable future, creating lucrative opportunities, especially with major developments in AI and analytics improvements through the coming decade
Loading Table Of Content...
